title: Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.
abstract: Human immunodeficiency virus-infected women with central adiposity switched to raltegravir-based antiretroviral therapy immediately or after 24 weeks. No statistically significant changes in computed tomography-quantified visceral adipose tissue (VAT) or subcutaneous fat were observed, although 48 weeks of raltegravir was associated with a 6.4% VAT decline. Raltegravir for 24 weeks was associated with improvements in lipids.
authors.affiliation: Department of Medicine , University of California, Los Angeles, California.
authors.forename: Jordan E
authors.initials: JE
authors.lastname: Lake
authors.affiliation: Department of Pediatrics and Medicine , Case Western Reserve University , Cleveland, Ohio.
authors.forename: Grace A
authors.initials: GA
authors.lastname: McComsey
authors.affiliation: Department of Medicine , Vanderbilt University , Nashville, Tennessee.
authors.forename: Todd
authors.initials: T
authors.lastname: Hulgan
authors.affiliation: Department of Medicine , Tufts University , Boston, Massachusetts.
authors.forename: Christine A
authors.initials: CA
authors.lastname: Wanke
authors.affiliation: Department of Medicine , Tufts University , Boston, Massachusetts.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Mangili
authors.affiliation: Department of Medicine , University of Toronto , Ontario , Canada.
authors.forename: Sharon L
authors.initials: SL
authors.lastname: Walmsley
authors.affiliation: Department of Medicine , University of California, Los Angeles, California.
authors.forename: Judith S
authors.initials: JS
authors.lastname: Currier
keywords: HIV; antiretroviral therapy; fat; raltegravir; visceral; women